Equibles does not estimate personal net worth.
Get an email with a short summary when Eton Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ETON alertsJames Gruber is recorded as CFO at Eton Pharmaceuticals, Inc. (ETON). The newest filing on record that lists James Gruber as CFO at Eton Pharmaceuticals, Inc. (ETON) is dated April 24, 2026. The proxy statement of Eton Pharmaceuticals, Inc. reports total compensation of $785,140 for James Gruber in fiscal 2023, including a base salary of $379,167. Disclosed compensation is on record for 3 fiscal years. James Gruber has spoken on 17 earnings calls across 1 company, most recently for Eton Pharmaceuticals, Inc. on May 14, 2026. Eton Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Eton Pharmaceuticals, Inc. includes Sean Brynjelsen (CEO and Board Member), Norbert G. Riedel (Chairman), Judith Matthews (CFO) and 4 others.
“First quarter revenue increased 40% to $24.3 million, compared to $17.3 million in the first quarter of 2025, and we had $3.3 million of licensing revenue in the first quarter of 2025.”
“Our fourth quarter revenue increased 83% to $21.3 million compared to $11.6 million in the fourth quarter of 2024, and revenue was comprised entirely of product sales in both periods.”
“Our third-quarter revenue increased 118% to $22.5 million compared to $10.3 million in the third quarter of 2024, and revenue was primarily comprised of product sales in both periods.”
“Turning to our financial results, our second quarter revenue was $18.9 million compared to $9.1 million in the second quarter of 2024, an increase of 108% and was comprised entirely of product sales.”
“I'll start by addressing the tariff situation in the U.S. since that seems to be at the top of everyone's list of questions right now. We believe Eton would see minimal impact from any of the tariff proposals discussed to date.”
Start not stated–present
Last confirmed April 24, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Eton Pharmaceuticals, Inc. (ETON) | Chief Financial Officer | $379,167 | $785,140 |
| 2022 | Eton Pharmaceuticals, Inc. (ETON) | Chief Financial Officer | $254,648 | $712,845 |
| 2021 | Eton Pharmaceuticals, Inc. (ETON) | Chief Financial Officer | — | — |
